NEW YORK, June 13 – Galapagos Genomics is collaborating with Bayer Yakuhin of Japan to identify and evaluate the function of proteins associated with asthma, the company announced Wednesday.
Galapagos, of Mechelen, Belgium, will construct recombinant adenoviruses containing asthma-associated human genes supplied by Bayer Yakuhin, a subsidiary of German pharmaceutical giant Bayer. Bayer Yakuhin will then use the viruses to introduce the genes into human cells, in order to discern how the proteins encoded by these genes work at a cellular level.
The parties did not disclose the financial terms of the collaboration.
Galapagos, a privately held company, has developed a PhenoSelect expression platform technology, in which it has arrayed adenoviruses with human genes. The company will use this proprietary platform in its collaboration.
“This is Galapagos’ first collaboration with a top-tier pharmaceutical company and it is therefore an important milestone for the company,” Galapagos CEO Onno van de Stolpe said in a statement. “This collaboration is an endorsement of our platform as an important tool in the rapid identification and validation of drug targets out of large gene collections.”